

ORIGINAL PROF-631 HER-2/neu OVER EXPRESSION; IMMUNOHISTOCHEMICAL DETERMINATION IN INVASIVE LOBULAR CARCINOMA OF BREAST

DR. SYED QAISER HUSSAIN NAQVI

Senior Demonstrator, Pathology Department, Peoples Medical College Nawabshah.

DR. QAMAR JAMAL

Professor, Pathology Department, Ziauddin Medical University Karachi.

DR. SYED MEHMOOD HASSAN ZAIDI Senior Lecturer, Pathology Department, Jinnah Medical College, Karachi.

Dr. Rana Khalid Mehmood

Assistant Professor, Pathology Department, Nishtar Medical College, Multan.

Dr. Fozia Abbas

Assistant Professor, Pathology Department, Sir Syed Medical College, Karachi.

ABSTRACT

D BJECTIVE: To determine the frequency of HER-2/neu over expression in invasive lobular carcinoma (ILC) of breast & correlate it with various standard prognostic parameters. **DESIGN:** This study was performed on formalin fixed paraffin embedded blocks of 18 diagnosed cases of invasive carcinoma of breast with classic lobular pattern. **PLACE:** Department of Pathology, Basic Medical Science Institute, Jinnah Postgraduate Medical Center, Karachi, Pakistan. **METHODS:** The paraffin block were retrieved and 5µm thick sections were cut and stained with H&E for the review of diagnosis and grading. The immunohistochemical staining was done on 4 µm thick sections by using polyclonal rabbit anti HER-2 ZYMED USA, and ZYMED 2nd generation LAB-SA immunodetection system, to see the HER-2/neu over-expression. **RESULTS:** Sections containing > 50% of tumor cells exhibiting intense circumferential cell membrane staining were scored as positive. The HER-2/neu over expression was seen in 22% of cases. **CONCLUSION:** The results in this study are statistically insignificant but positive cases can get benefit from Herceptin therapy.

KEYWORD: HER-2/neu, immunohistochemistry, invasive lobular carcinoma.

INTRODUCTION

Invasive lobular carcinoma (ILC) of breast accounts for 0.7-15% of all invasive malignancies of breast^{1,2,3,4}. A palpable mass is seen in majority of cases but some tumors are hard to detect even on mammography because of the diffuse growth pattern of cellular infiltrate. Since tumor cells tend to infiltrate beyond the

palpable extent of the tumor, resection margins are more frequently tumor positive⁴ and the recurrence rate is higher than the invasive ductal carcinoma (IDC)^{5,6}. These tumors are usually multifocal, multicentric & bilateral^{7,8,9}.

The ILC has a low frequency of nodal metastasis than IDC^{3,4}. Various workers have reported that ILC has

more favorable outcome and better prognosis than $IDC^{4,10}$. However the variants have less favorable prognosis^{11,12}. Several studies have found no significant difference in survival of patients in ILC & $IDC^{3,13}$, and some studies have found worse prognosis for ILC than IDC^{14} .

Nonetheless, it remains a challenge to predict, who are at greatest risk of poor prognosis. The discovery of the role-played by oncogenes in the genesis and progression of breast carcinoma has opened opportunities to explore their possible role as predictors of tumor behavior. Accumulating evidence indicates that abnormalities in expression of HER-2/neu gene are common in breast cancer and may be pathogenically significant^{15,16}.

The importance of HER-2/neu over-expression in the malignant process was inferred from discoveries of HER-2/neu gene amplification in some cases of human breast cancer¹⁷. The HER-2/neu oncogene has been the subject of heated debates during last decade concerning its prognostic significance for women with breast cancer¹⁸. But now HER-2/neu is thought to be an independent prognostic factor in patients with breast carcinoma¹⁹ and is predictor of shortened disease free survival, overall survival & poor clinical out-come in patients with breast carcinoma^{20,21}. More recent studies show that HER-2/neu over-expression has therapeutic implications in infiltrating breast carcinoma. The United States Food & Drug Administration has recently approved Herceptin (Trastuzumab) a monoclonal antibody against HER-2/neu which has therapeutic efficacy in HER-2/neu over expressing tumors.¹⁸.

There is great discrepancy in the results of various studies regarding HER-2/neu positive over-expression in invasive lobular carcinoma of breast. Majority of studies have not found any positive over-expression²²⁻²⁵ & some have found positive over expression of HER-2/neu in ILC^{26,27}, keeping in view of all the above facts, the present study was designed to see the frequency of HER-2/neu over-expression in classic cases of invasive lobular carcinoma of breast and to correlate the positive index, with the age of patients at the time of diagnosis, nodal status, grade and size of tumor.

MATERIAL & METHODS

The present study was performed at the department of

pathology, Basic Medical Sciences Institute, Jinnah Postgraduate Medical Centre, Karachi, Pakistan on formalin fixed paraffin embedded blocks of 18 diagnosed cases of invasive carcinoma of breast with classic lobular pattern.

 5μ m thick sections were cut and stained with H & E for the review of diagnosis. Grading was done by Notingham Modification of the Bloom Richardson System.

IMMUNOHISTOCHEMICAL STAINING

Polyclonal Rabbit anti HER-2 ZYMED USA and ZYMED 2nd generation LAB-SA immunodetection system was used.

Sections were prepared for immunohistochemical staining of 4 μ m thickness from representative paraffin embedded blocks. Poly L-lysine coated slides were used. The sections were allowed to dry in an oven at 56-60°C for one hour.

STEPS

Deparafinization

Two changes of xylene for 5 minutes each.

Rehydration

Two changes each for 3 minutes in decreasing concentration of alcohol starting from absolute to 70%, rinsing with tap water at the end.

Antigen retrieval

Heat induced epitope retrieval (HIER) method was used. Slides were left in phosphate buffer saline (PBS) for 30 minutes at room temperature.

Serum blocking agent

Applied over the encircled area, kept for 10 minutes, and then solution was drained off.

Primary antibody

Primary antibody was applied and left for 60 minutes. Slides were rinsed with PBS buffer.

Secondary antibody

Biotinylated secondary antibody applied and left for 20 minutes and slides were rinsed with PBS buffer.

Enzyme conjugate

Application of streptavidin alkaline phosphatase for 20 minutes. Slides were drained and rinsed with PBS buffer.

Substrate chromogen solution (Fast red) Applied over the section and left for 10 minutes. Slides rinsed with PB buffer.

Counter stain Mayer's hematoxylin was used for counter stain.

MOUNTING

Section were mounted with Faramount aqueous base mounting medium.

INTERPRETATION OF RESULTS

The tumor was interpreted as positive for overexpression of HER-2/neu protein product when > 50% of the tumor cells gave circumferential intense fast red membrane staining, which was identified with a 10 x and confirmed with 40 x objectives. Cytoplasmic staining without membranous staining was considered as negative for HER-2/neu overexpression.

STATISTICAL ANALYSIS

The computer package "Microsoft Excel" was used for data feeding and "EPI-INFO" was used for statistical analysis. The results were given in the text as number and percentage for qualitative variables. To compare proportion / percentage between groups by Chi-square test. In all statistical analysis, only p-values <0.05 are considered significant.

RESULTS

In this study, 18 cases of classic invasive lobular carcinoma were subjected to immunohistochemical staining for HER-2/neu over-expression.

Out of these, 4 (22%) exhibited intense circumferential cell membrane staining with additional focal cytoplasmic staining in > 50% of tumor cells and these cases scored as positive for HER-2/neu over-expression (Fig-1).




Figure-1. Invasive lobular carcinoma. Revealing intense circumferential membranous with cytoplasmic staining, positive HER-2/neu over-expression by immuno-histochemistry x 1440.

Table-I. HER-2 Over-expression compared to	
lymph node status	

Lymph node status	No of patients	HER-2 positive over-expression	%age
-	5	-	-
1-3	7	3	43
>3	6	1	17
			0.05

Compared lymph node status P value was >0.05 (insignificant)

The various prognostic factors including lymph node status, grade, size of tumor and age of patient were evaluated (table I-IV) but none of them achieved statistical significance.

Table-II. HER-2 Over-expression compared to grade of tumor			
Circle	No of patients	HER-2 positive over- expression	%age
I	7	1	14
II	6	1	17
III	5	2	40
Comparing grade tumor P value was >0.05 (insignificant)			

Table-III. HER-2 Over-expression compared to size of tumor			
Size (cm)	No of patients	HER-2 positive over- expression	%age
≤ 2.0	5	1	20
2.1 - 5.0	5	1	20
≥5.1	8	2	25
Comparing size tumor P value was >0.05 (insignificant)			

Table-IV. HER-2 Over-expression compared to age
of patient

Age (yrs)	No of patients	HER-2 positive over- expression	%age
≤35	1	-	-
36 - 50	11	2	18
≥51	6	2	33

Comparing age patient, P value was >0.05 (insignificant)

DISCUSSION

Compared to the invasive ductal carcinoma a vary little work has been done on invasive lobular carcinoma of breast. Most of the researchers were unable to find any positive over expression in ILC^{22-25}

In this study, we found 22% positive over expression of HER-2/neu, confirming the results of those previous studies which found the positive over-expression of HER-2/neu oncoprotein^{26,27}.

CONCLUSION

Although, we could not find any statistically significant result, but the data of this study shows that by the help of HER-2/neu oncoprotein as a marker high risk patients can be detected.

REFERENCES

- Page DL. Prognosis and breast cancer, recognition of lethal and favorable prognostic types. Am J Surg Pathol 1991; 15: 334.
- 2. Anderson TJ, Lamb J, Donnan P et al. Comparative

pathology of breast cancer in a randomized trial of screening. Br J Cancer 1991; 64: 108.

- 3. Sastre-Garau X, Jouve M, Asselain B et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with references to data on conservative therapy and metastatic patterns. Cancer 1996; 77: 113-120.
- 4. Silverstein MJ, Lewinsky BS, Waisman JR et al. Infiltration lobular carcinoma. Is it different from infiltrating duct carcinoma? Cancer 1994; 73: 1673-1677.
- 5. Schnitt SJ, Connolly IL, Recht A et al. Influence of infiltrating lobular histology on local tumor control in breast cancer patients treated with conservative surgery and radiotherapy. Cancer 1989; 64: 448-454.
- 6. Kurtz JM, Jacquemier J, Thorst J et al. Conservation therapy for breast cancer other than infiltrating ductal carcinoma. Cancer 1989; 63: 1630-1635.
- Fisher E, Gregorio R Redmond C et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no 4) 1: Observation concerning the multicetricity of mammary cancer. Cancer 1975; 35: 247-254.
- Dixon JM, Anderson TJ, Page DL et al. Infiltrating lobular carcinoma of the breast, an avaluation of the incidence and consequences of bilateral disease. Br. J. Surg 1983; 70: 513-517.
- 9. Holland PA, Shah A, Howell A et al. Lobular carcinoma of the breast can be managed by breast conserving therapy. Br J Surg 1995; 82: 1364-1366.
- Toikannen S, Pylkkanen L, Joensuu H. Invasive lobular carcinoma of the breast has better short and long term survival than invasive ductal carcinoma. Br J Cancer 1997; 76: 1234-1240.
- 11. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 1992; 23: 1167-1171.
- 12. Dixon JM, Anderson TJ, Page DL et al.Infiltrating lobular carcinoma of the breast. Histopathology 1982; 6:149-161.
- Ashikari R, Huvos AG, Urban JA, et al. Infiltrating lobular carcinoma of the breast. Cancer 1973; 31: 110-116.

4

- Mc Divit RW, Stewart FW, Berg JW. Tumors of the breast Atlas of tumor pathology, 2nd series fascicle 2. Washington, DC, Armed Forces Institute of Pathology 1968; p-82.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A. McGuire WL. Human breast cancer. Correlation of relapse and survival with amplification of the HER-2/neu. Oncogene. Science 1987; 235: 1238-1243.
- Ali IU, Campbell G, Lidereau R and Callahan R. Amplification of cerb B-2 and aggressive human breast tumor? Science (Washington DC) 1988; 240: 1795-1796.
- King CR, Kraus MH and Aaronson SA. Amplification of a novel verbB-related gene in a human mammary carcinoma. Science (Washington DC) 1985; 229: 974-976.
- Vang R, Cooley LD, Harrison WR, Reese T, Abrams J. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. Am J Clin. Pathol 2000; 113: 669-674.
- Kacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Her-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol. 2000; 113: 251-258.
- Ross JS and Fletcher JA. Her-2/neu (c-erb-B2) gene and protein in breast cancer. Am J. Clin. Pathol. 1999; 112(suppl.1): S53-S67.

- 21. Hoang MP, Sahin AA, Ordonex NG, Sneige N. Her-2/neu Gene amplification compared with HER-2/neu protein over expression and inter observer reproducibility in invasive breast carcinoma. Am J. Clin. Pathol. 2000; 113: 852-859.
- 22. Porter PL, Garcia R, Moe P. Corwin DJ, Gown AM. C-erbB-2 oncogene protein in situ and invasive lobular breast neoplasia. Cancer 1991; 68: 331-334.
- Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer. A 30 year follow-up. J. Clin. Oncol. 1992; 10: 1044-1048.
- Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of c-erbB-2 expression in breast cancer. J.Clin Oncol. 1992; 10(7): 1049-1056.
- 25. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD. P53 and c-erb B-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferatioin markers and clinical stage in human breast cancer. Am. J. Clin. Pathol. 1992; 98(4): 408-418.
- 26. Tetu B and Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73:2359-2365.
- 27. Keshgegian AA, Cnaan A. Proliferatioin markers in breast carcinoma. Mitotic figure count, S-Phase fraction, proliferating cell nuclear antigen, Ki-67 and MIBI. Am. J. Clin. Pathol 1995; 104: 42-49.